Why Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?

November 27, 2023

https://www.benzinga.com/general/biotech/23/11/35957635/why-is-gastrointestinal-disease-focused-redhill-biopharma-stock-higher-over-100-today

Why Is Gastrointestinal Disease Focused-RedHill Biopharma Stock Higher Over 100% Today?
The FDA has granted five years' market exclusivity for RedHill Biopharma Ltd's (NASDAQ:RDHL) Talicia under the Generating Antibiotic Incentives Now Act Qualified Infectious Disease Product designation, as recommended by the 
https://www.benzinga.com/general/biotech/23/11/35957635/why-is-gastrointestinal-disease-focused-redhill-biopharma-stock-higher-over-100-today

Related news for (RDHL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.